Evaluation of CYP2C19 Genetic Variant and Its Lack of Association with Valproic Acid Plasma Concentrations Among Zhuang and Han Schizophrenia Patients in Guangxi

References

• White C, Scott R, Paul CL, et al. Pharmacogenomics in the era of personalised medicine. Med J Aust. 2022;217(10):510–513. doi:10.5694/mja2.51759
   PubMed Web of Science ®Google Scholar
• Weinshilboum RM, Wang L. Pharmacogenomics: precision medicine and drug response. Mayo Clin Proc. 2017;92(11):1711–1722. doi:10.1016/j.mayocp.2017.09.001
   PubMed Web of Science ®Google Scholar
• Abbasi J. Getting pharmacogenomics into the clinic. JAMA. 2016;316(15):1533–1535. doi:10.1001/jama.2016.12103
   PubMed Web of Science ®Google Scholar
• Hockings JK, Pasternak AL, Erwin AL, et al. Pharmacogenomics: an evolving clinical tool for precision medicine. Cleve Clin J Med. 2020;87(2):91–99. doi:10.3949/ccjm.87a.19073
   PubMed Web of Science ®Google Scholar
• Cecchin E, Stocco G. Pharmacogenomics and personalized medicine. Genes. 2020;11(6):679. doi:10.3390/genes11060679
   PubMed Web of Science ®Google Scholar
• Scott SA, Sangkuhl K, Shuldiner AR, et al. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genomics. 2012;22(2):159–165. doi:10.1097/FPC.0b013e32834d4962
   PubMed Web of Science ®Google Scholar
• Stajnko A, Runkel AA, Kosjek T, et al. Assessment of susceptibility to phthalate and DINCH exposure through CYP and UGT single nucleotide poly- morphisms. Environ Int. 2022;159:107046. doi:10.1016/j.envint.2021.107046
   PubMed Web of Science ®Google Scholar
• Biswas M, Shobana J, Jinda P, et al. Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine. Expert Opin Drug Metab Toxicol. 2023;19(3):165–174. doi:10.1080/17425255.2023.2203860
   PubMed Web of Science ®Google Scholar
• Jukić MM, Haslemo T, Molden E, et al. Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: a retrospective study based on 2087 patients. Am J Psychiatry. 2018;175(5):463–470. doi:10.1176/appi.ajp.2017.17050550
   PubMed Web of Science ®Google Scholar
• Bernal CJ, Aka I, Carroll RJ, et al. CYP2C19 phenotype and risk of proton pump inhibitor-associated infections. Pediatrics. 2019;144(6):e20190857. doi:10.1542/peds.2019-0857
   PubMed Web of Science ®Google Scholar
• Lee CR, Luzum JA, Sangkuhl K, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clin Pharmacol Ther. 2022;112(5):959–967. doi:10.1002/cpt.2526
   PubMed Web of Science ®Google Scholar
• Uppugunduri CR, Daali Y, Desmeules J, et al. Transcriptional regulation of CYP2C19 and its role in altered enzyme activity. Curr Drug Metab. 2012;13(8):1196–1204. doi:10.2174/138920012802850146
   PubMed Web of Science ®Google Scholar
• Hicks JK, Bishop JR, Sangkuhl K, et al.; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98(2):127–134. doi:10.1002/cpt.147
   PubMed Web of Science ®Google Scholar
• Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: 2017 edition. Pract Pharm Clin Remedies. 2022;25(02):97–118. Chinese.
   Google Scholar
• Tseng YJ, Huang SY, Kuo CH, et al. Safety range of free valproic acid serum concentration in adult patients. PLoS One. 2020;15(9):e0238201. doi:10.1371/journal.pone.0238201
   PubMed Web of Science ®Google Scholar
• Lin K, Cao VFS, Au C, et al. Clinical pharmacokinetic monitoring of free valproic acid levels: a systematic review. Clin Pharmacokinet. 2022;61(10):1345–1363. doi:10.1007/s40262-022-01171-w
   PubMed Web of Science ®Google Scholar
• Thummel KE, Shen DD. Design and optimization of dosage regimens: pharmacokinetic data. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill; 2001:1917–2023.
   Google Scholar
• Song C, Li X, Mao P, et al. Impact of CYP2C19 and CYP2C9 genetic variants on sodium valproate plasma concentration in patients with epilepsy. Eur J Hosp Pharm. 2022;29(4):198–201. doi:10.1136/ejhpharm-2020-002367
   PubMedGoogle Scholar
• López-García MA, Feria-Romero IA, Serrano H, et al. Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy. Pharmacol Rep. 2017;69(3):504–511. doi:10.1016/j.pharep.2017.01.007
   PubMed Web of Science ®Google Scholar
• Han R, Li Y, Wu W. Effects of CYP2C19 genetic polymorphism on plasma concentration of sodium valproate in epileptic patients. Neural Injury Funct Reconstr. 2015;10:295–297.
   Google Scholar
• Wang S, Li J, Song M, et al. Effect of CYP2C19 polymorphisms on serum valproic level acid in Chinese Han patients with schizophrenia. Sci Rep. 2021;11(1):23150. doi:10.1038/s41598-021-02628-x
   PubMed Web of Science ®Google Scholar
• Smith RL, Haslemo T, Refsum H, et al. Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid—a large-scale study based on naturalistic therapeutic drug monitoring data. Eur J Clin Pharmacol. 2016;72(9):1–6. doi:10.1007/s00228-016-2087-0
   PubMed Web of Science ®Google Scholar
• Fricke-Galindo I, Céspedes-Garro C, Rodrigues-Soares F, et al. Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and “measured” metabolic phenotypes across world populations. Pharmacogen J. 2015;16(2):113–123. doi:10.1038/tpj.2015.70
   PubMed Web of Science ®Google Scholar
• He L, Chen S, Li J, et al. Genetic and phenotypic frequency distribution of CYP2C9, CYP2C19 and CYP2D6 in over 3200 Han Chinese. Clin Exp Pharmacol Physiol. 2020;47(10):1659–1663. doi:10.1111/1440-1681.13357
   PubMed Web of Science ®Google Scholar
• Shu Y, Zhou HH. Individual and ethnic differences in CYP2C19 activity in Chinese populations. Zhong Guo Yao Li Xue Bao. 2000;21(3):193–199.
   PubMed Web of Science ®Google Scholar
• Yin SJ, Ni YB, Wang SM, et al. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations. J Clin Pharm Therapeutics. 2012;37(3):364–369. doi:10.1111/j.1365-2710.2011.01298.x
   PubMed Web of Science ®Google Scholar
• Ruan FW, Yang WY, Chen XL, et al. Analysis of distribution characteristics of CYP2C19 gene polymorphism in Han nationality patients with coronary heart disease in Dongguan. Lab Med Clinic. 2020;17(3):3. Chinese.
   Google Scholar
• Bao Y, Qian FC, Fu TG, et al. Analysis of CYP2C19 gene polymorphism in population of Huzhou area. Chin J Health Lab Technol. 2022;32(19):4. Chinese.
   Google Scholar
• Jin SL, Yan HM, Wu Y, et al. Analysis of the relationship between CYP2C19 gene polymorphism and valproic acid metabolism in han Chinese patients with mental illness in Hebei Province. Hebei Med. 2023;29(1):97–102. Chinese.
   Google Scholar
• Zuo LJ, Guo T, Xia DY, et al. Allele and Genotype Frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese Populations. Genet Test Mol Biomar. 2012;16(2):102–108. doi:10.1089/gtmb.2011.0084
   PubMed Web of Science ®Google Scholar
• Wang SM, Zhu AP, Li D, et al. Frequencies of genotypes and alleles of the functional SNPs in CYP2C19 and CYP2E1 in mainland Chinese Kazakh, Uygur and Han populations. J Hum Genet. 2009;54(6):372–375. doi:10.1038/jhg.2009.41
   PubMed Web of Science ®Google Scholar
• López-Fernández LA. Pharmacogenetics to avoid adverse drug reactions. J Personal Med. 2022;12(2):159. doi:10.3390/jpm12020159
   PubMed Web of Science ®Google Scholar
• Ma WB, Zhang LT, Ren XD, et al. Distribution of CYP2C19 gene polymorphisms in different sex, age and ethnio groups of patients with coronary heart disease in Shaanxi province and a comparative analysis with other areas in China. Int J Lab Med. 2020;41(5):5. Chinese.
   Google Scholar
• Li J, Wang YX, Wang HP, et al. Distribution of CYP2C19 polymorphisms in Mongolian and Han nationals and the choice of specific antiplatelet drugs. Int J Clin Pharm. 2017;39(4):791–797. doi:10.1007/s11096-017-0451-5
   PubMed Web of Science ®Google Scholar
• Zhang S, Luo J, Xu Q, et al. Analysis of CYP2C19 gene polymorphism and metabolic phenotype in Alzheimer’s disease patients of Han Nationality in Guizhou. J Mod Lab Med. 2020;35(5):4. Chinese.
   Google Scholar
• Huan LJ, Wang PY. Analysis of CYP2C19*2 and *3 locus gene polymorphisms in elderly Han population of Hubei. Int J Lab Med. 2021;42(24):3014–3017. Chinese.
   Google Scholar
• Zhang JY, Yang XB, Li Y, et al. Preliminary study on CYP2C19gene polymorphism in patients with coronary heart disease in Yunnan province. Chin J Hospital Pharm. 2021;41(1):4. Chinese.
   Google Scholar
• Jiang XR, Zhang YG, Lu J, et al. Distribution of CYP2C19 genetic polymorphisms in a north Chinese Han population with digestive tract diseases. Chin J Clin Exper Pathol. 2016;32(10):5. Chinese.
   Google Scholar
• Wang Y, Zhao X, Lin J, et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA. 2016;316(1):70–78. doi:10.1001/jama.2016.8662
   PubMed Web of Science ®Google Scholar
• Botton MR, Whirl-Carrillo M, Del Tredici AL, et al. PharmVar GeneFocus: CYP2C19. Clin Pharmacol Ther. 2021;109(2):352–366. doi:10.1002/cpt.1973
   PubMed Web of Science ®Google Scholar
• Guo J, Huo Y, Li F, et al. Impact of gender, albumin, and CYP2C19 polymorphisms on valproic acid in Chinese patients: a population pharmacokinetic model. J Int Med Res. 2020;48(8):300060520952281. doi:10.1177/0300060520952281
   PubMed Web of Science ®Google Scholar
• Wu ZT, Wang GH, Xiao L, et al. Effect of CYP2C19 gene polymorphism on liver function changes induced by high valproic acid dosages in patients with bipolar disorder. Med J Wuhan Univ. 2021;42(01):119–122. Chinese.
   Google Scholar
• Ghodke-Puranik Y, Thorn CF, Lamba JK, et al. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genom. 2013;23(4):236–241. doi:10.1097/FPC.0b013e32835ea0b2
   PubMed Web of Science ®Google Scholar
• Inoue K, Suzuki E, Yazawa R, et al. Influence of uridine diphosphate glucuronosyltransferase 2B7 −161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients. Therap Drug Monitor. 2014;36(3):406. doi:10.1097/FTD.0000000000000012
   PubMed Web of Science ®Google Scholar
• Karle J, Bolbrinker J, Vogl S, et al. Influence of CYP2D6 genotype on tamoxifen efficacy in advanced breast cancer. Breast Cancer Res Treat. 2014;139(2):553–560. doi:10.1007/s10549-013-2565-3
   Web of Science ®Google Scholar
• Kiss ÁF, Vaskó D, Déri MT, et al. Combination of CYP2C19 genotype with non-genetic factors evoking phenoconversion improves phenotype prediction. Pharmacol Rep. 2018;70(3):525–532. doi:10.1016/j.pharep.2017.12.001
   PubMed Web of Science ®Google Scholar
• de Jong LM, Boussallami S, Sánchez-López E, et al. The impact of CYP2C19genotype on phenoconversion by concomitant medication. Front Pharmacol. 2023;14:1201906. doi:10.3389/fphar.2023.1201906
   PubMed Web of Science ®Google Scholar
• Miura M, Tada H, Yasui-Furukori N, et al. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. Br J Clin Pharmacol. 2005;60(1):61–68. doi:10.1111/j.1365-2125.2005.02381.x
   PubMed Web of Science ®Google Scholar
• Ohnishi A, Murakami S, Akizuki S, et al. In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease. Clin Pharmacol. 2005;45(11):1221–1229. doi:10.1177/0091270005280787
   Google Scholar
• Veringa A, Ter Avest M, Span LF, et al. Voriconazole metabolism is influenced by severe inflammation: a prospective study. Antimicrob Chemother. 2017;72(1):261–267. doi:10.1093/jac/dkw349
   Google Scholar
• Shah RR, Smith RL. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine. Drug Metab Dispos. 2015;43(3):400. doi:10.1124/dmd.114.061093
   PubMed Web of Science ®Google Scholar
• Stanke-Labesque F, Gautier-Veyret E, Chhun S, et al. Inflammation is a major regulator of drug metabolizing enzymes and transporters: consequences for the personalization of drug treatment. Pharmacol Ther. 2020;215(9):107627. doi:10.1016/j.pharmthera.2020.107627
   PubMedGoogle Scholar
• Contreras-Shannon V, Heart DL, Paredes RM, et al. Clozapine-induced mitochondria alterations and inflammation in brain and insulin-responsive cells. PLoS One. 2013;8(3):e59012. doi:10.1371/journal.pone.0059012
   PubMed Web of Science ®Google Scholar
• Himmerich H, Schönherr J, FuLda S, et al. Impact of antipsychotics on cytokine production in-vitro. J Psychiatr Res. 2011;45(10):1358–1365. doi:10.1016/j.jpsychires.2011.04.009
   PubMed Web of Science ®Google Scholar
• Liao QC, Shi JJ, Zhang Y, et al. Effects of cytochrome P450 isozymes 2A6, 2B6, 2C9 and 2C19 genetic polymorphisms on plasma concentration of sodium valproate. Chin J Neurol. 2013;46(2):82–86. Chinese.
   Google Scholar
• Yoon HY, Min HA, Yee J, et al. Influence of CYP2C9 and CYP2A6 on plasma concentrations of valproic acid: a meta-analysis. Eur J Clin Pharmacol. 2020;76(8):1053–1058. doi:10.1007/s00228-020-02872-6
   PubMed Web of Science ®Google Scholar
• Kiang TKL, Ho PC, Reza AM, et al. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol Sci. 2006;94(2):261–271. doi:10.1093/toxsci/kfl096
   PubMed Web of Science ®Google Scholar
• Mei S, Feng W, Zhu L, et al. Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model. Eur J Clin Pharmacol. 2018;74(8):1029–1036. doi:10.1007/s00228-018-2440-6
   PubMed Web of Science ®Google Scholar
• Song C, Li X, Zhang H, et al. Impact of MDR1 and UGT gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy. Clin Lab. 2022;68(10):326–351. doi:10.7754/Clin.Lab.2022.220101
   Google Scholar
• Guo Y, Hu C, He X, et al. Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy. Drug Metab Pharmacokinet. 2012;27(5):536–542. doi:10.2133/dmpk.DMPK-11-NT-144
   PubMed Web of Science ®Google Scholar
• Liu MX. Pharmacokinetics of Valproic Acid Population and Meta-Analysis of the Effect of CYP2C19 Gene Polymorphism on Valproic Acid Plasma Concentration. Shihezi University; 2020. Chinese.
   Google Scholar
• Wang Y, Hu W, Li Z. Influence of age and co-medication on the concentration and efficacy of valproic acid in Chinese epilepsy children. Pak J Pharm Sci. 2020;33(2):537–542.
   PubMed Web of Science ®Google Scholar
• Chen R. Impact of CYP2C19 Genotypes on Serum Concentrations of Valproic Acid in Epileptic Children. Fujian Medical University; 2017. Chinese.
   Google Scholar
• Methaneethorn J. A systematic review of population pharmacokinetics of valproic acid. Br J Clin Pharmacol. 2018;84(5):816–834. doi:10.1111/bcp.13510
   PubMed Web of Science ®Google Scholar
• Kalthoff S, Winkler A, Freiberg N, et al. Gender matters: estrogen receptor alpha (ERα) and histone deacetylase (HDAC) 1 and 2 control the gender-specific transcriptional regulation of human uridine diphosphate glucuronosyltransferases genes (UGT1A). J Hepatol. 2013;59(4):797–804. doi:10.1016/j.jhep.2013.05.028
   PubMed Web of Science ®Google Scholar
• Ibarra M, Vázquez M, Fagiolino P, et al. Sex related differences on valproic acid pharmacokinetics after oral single dose. J Pharmacokinet Pharmacodyn. 2013;40(4):479–486. doi:10.1007/s10928-013-9323-3
   PubMed Web of Science ®Google Scholar
• Alqahtani S, Alandas N, Alsultan A. Estimation of apparent clearance of valproic acid in adult Saudi patients. Int J Clin Pharm. 2019;41(4):1056–1061. doi:10.1007/s11096-019-00864-w
   PubMed Web of Science ®Google Scholar
• Usman M, Shaukat QU, Khokhar MI, et al. Comparative pharmacokinetics of valproic acid among Pakistani and South Korean patients: a population pharmacokinetic study. PLoS One. 2022;17(8):e0272622. doi:10.1371/journal.pone.0272622
   PubMed Web of Science ®Google Scholar
• Mani B, Nair P, Sekhar A, et al. CYP2C19 & UGT1A6 genetic polymorphisms and the impact on Valproic acid-induced weight gain in people with epilepsy: prospective genetic association study. Epilepsy Res. 2021;177:106786. doi:10.1016/j.eplepsyres.2021.106786
   PubMed Web of Science ®Google Scholar